You just read:

BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME

News provided by

BioInvent

20 Aug, 2019, 09:54 BST